Skip to content

Welcome to Discover Pharma! Today is : November 8, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Drug Discovery & Development

  • Drug Delivery & Formulation,Drug Discovery & Development,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics,Research & Development

    ProBioGen and VarmX partner on second Factor X candidate

    ProBioGen and VarmX have entered a collaboration to develop a [...]

    July 29, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Manufacturing & Supply Chain,Medical devices,Research & Development

    Pioneer launches regional accelerator programmes for life science and tech start-ups

    Pioneer Group has launched regional accelerator programmes in Cambridge and [...]

    July 24, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Kairos Pharma and Bayer to evaluate ENV-105 combination in prostate cancer

    Kairos Pharma and Bayer will evaluate ENV-105 in combination with [...]

    July 23, 2026
  • Biotech & Pharma Business,Digital & Data,Drug Discovery & Development,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics,Research & Development

    India’s CDMO market needs science, not just scale, says Lupin Manufacturing Solutions CEO

    In this exclusive interview with Liza Laws for Discover Pharma, [...]

    July 23, 2026
  • Digital & Data,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development

    Deep Origin computational platform identifies potent molecular glue for lymphoma treatment

    Deep Origin’s computational platform helped identify a molecular glue compound [...]

    July 22, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Research & Development,Therapeutic Areas

    NEJM study provides first clinical evidence for NET-degrading therapy in lupus

    A study published in The New England Journal of Medicine [...]

    July 17, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Research & Development,Therapeutic Areas

    Kairos reports positive interim Phase 1 safety data for ENV-105 in EGFR-mutated lung cancer

    Kairos Pharma has reported positive interim safety results from an [...]

    July 16, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics

    Adneuris licenses Phase 3 pain therapy cebranopadol to Conba for Greater China

    Adneuris Therapeutics has granted Zhejiang Conba Pharmaceutical exclusive rights to [...]

    July 15, 2026
  • Digital & Data,Drug Discovery & Development,Research & Development

    Latent Labs opens lab-validated AI drug design platform to researchers worldwide

    Latent Labs has launched its artificial intelligence-powered drug design platform [...]

    July 15, 2026
  • Digital & Data,Drug Discovery & Development,Research & Development,Therapeutic Areas

    Nucs AI taps Segmed’s 150 million imaging studies to strengthen oncology AI

    Nucs AI has partnered with healthcare data specialist Segmed to [...]

    July 15, 2026
Previous8910Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • BridgeBio gets FDA Priority Review for oral infigratinib in achondroplasia
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • ViiV’s Cabenuva achieves superior viral suppression in CROWN Phase 3b study
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Shift Bioscience publishes AI virtual cell framework for target discovery
    Categories: Digital & Data, Drug Discovery & Development, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top